Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 221 - 230 of 371

Selected Filters:
7 July 2022

Healthcare Worker Guide to Providing PrEP

Calling all healthcare providers! This video is for you, as we outline some top tips and guidance on prescribing PrEP. We want to empower you with the information you need about PrEP, inform you on how best to counsel your client on what’s right for them, and support them in a non-judgmental manner. This is…

Community/Advocacy, Demand Creation/Marketing

External Link
7 July 2022

Health Care Providers’ Attitudes toward and Experiences Delivering Oral PrEP to Adolescent Girls and Young Women in Kenya, South Africa, and Zimbabwe

This article describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Kenya, South Africa, and Zimbabwe offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

External Link
7 July 2022

Health care providers’ attitudes toward and experiences delivering oral PrEP to adolescent girls and young women: Kenya technical brief

This technical brief describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Kenya offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

Health care providers’ attitudes toward and experiences delivering oral PrEP to adolescent girls and young women: Zimbabwe technical brief

This technical brief describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Zimbabwe offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

The Years Ahead in Biomedical HIV Prevention Research

This graphic shows the updated status of large-scale prevention trials through 2024.

Community/Advocacy

External Link
7 July 2022

Pre-Exposure Prophylaxis: An introductory factsheet

This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.

Community/Advocacy

External Link
7 July 2022

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

External Link
7 July 2022

DISCOVER Trial Factsheet

This factsheet provides details on the DISCOVER trial to assess whether F/TAF (trade name Descovy) is as safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product.

Community/Advocacy, Research

External Link
7 July 2022

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

External Link
7 July 2022

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies

External Link